![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Leukemia |
Free Subscription
2 Am J Hematol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Leukemia is free of charge.
Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic
Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and
Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized
Trial.
Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26620.
PubMed
Abstract available
Incident users of tyrosine kinase inhibitors in chronic myeloid leukemia
patients: analysis of anticancer treatment trajectories - A French
population-based study using the French national health data system.
Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26621.
PubMed
Severe platelet transfusion refractoriness due to anti-HPA-5a antibody during
induction chemotherapy for acute promyelocytic leukemia.
Ann Hematol. 2022 May 25. pii: 10.1007/s00277-022-04875.
PubMed
Relapse surveillance of acute myeloid leukemia patients in first remission after
consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.
Ann Hematol. 2022 May 20. pii: 10.1007/s00277-022-04862.
PubMed
Abstract available
Interrogating molecular genetics to refine LGLL classification.
Blood. 2022;139:3002-3004.
PubMed
Role of CDH23 as a prognostic biomarker and its relationship with immune
infiltration in acute myeloid leukemia.
BMC Cancer. 2022;22:568.
PubMed
Abstract available
Volasertib as a monotherapy or in combination with azacitidine in patients with
myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid
leukemia: summary of three phase I studies.
BMC Cancer. 2022;22:569.
PubMed
Abstract available
Additional cytogenetic features determines outcome in patients allografted for
TP53 mutant acute myeloid leukemia.
Cancer. 2022 May 25. doi: 10.1002/cncr.34268.
PubMed
Abstract available
CRLF2 overexpression results in reduced B-cell differentiation and upregulated
E2F signaling in the Dp16 mouse model of Down syndrome.
Exp Hematol. 2022;110:34-38.
PubMed
Abstract available
Presence of mutant p53 increases stem-cell frequency and is associated with
reduced binding to classical TP53 binding sites in cell lines and primary AMLs.
Exp Hematol. 2022 Mar 18. pii: S0301-472X(22)00128.
PubMed
Abstract available
ERG amplification is a secondary recurrent driver event in myeloid malignancy
with complex karyotype and TP53 mutations.
Genes Chromosomes Cancer. 2022;61:399-411.
PubMed
Abstract available
RNA-binding proteins as drivers of AML and novel therapeutic targets.
Leuk Lymphoma. 2022;63:1045-1057.
PubMed
Abstract available
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes.
Leuk Lymphoma. 2022;63:1227-1235.
PubMed
Abstract available
RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD
positive AML, both in vitro and in vivo.
Leuk Lymphoma. 2022;63:1167-1179.
PubMed
Abstract available
Genetic changes during leukemic transformation to secondary acute myeloid
leukemia from myeloproliferative neoplasms.
Leuk Res. 2022;118:106858.
PubMed
Abstract available
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022
update of the recommendations by ERIC, the European Research Initiative on CLL.
Leukemia. 2022 May 25. pii: 10.1038/s41375-022-01604.
PubMed
Abstract available
Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid
leukemia at its core.
Leukemia. 2022 May 24. pii: 10.1038/s41375-022-01603.
PubMed
Inability to phosphorylate Y88 of p27(Kip1) enforces reduced p27 protein levels
and accelerates leukemia progression.
Leukemia. 2022 May 21. pii: 10.1038/s41375-022-01598.
PubMed
Abstract available
Use of CRISPR/Cas9 with homology-directed repair to silence the human
topoisomerase IIalpha intron-19 5' splice site: Generation of etoposide
resistance in human leukemia K562 cells.
PLoS One. 2022;17:e0265794.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by